Ceftaroline fosamil monotherapy for methicillin-resistant Staphylococcus aureus bacteremia: a comparative clinical outcomes study

Abstract

CPT-F demonstrated comparable clinical outcomes in MRSA bacteremia patients compared with the other agents, especially as salvage therapy.

Pharmacodynamic comparison of different antimicrobial regimens against Staphylococcus aureus bloodstream infections with elevated vancomycin minimum inhibitory concentration

“…However, increasing reports of reduced susceptibility to vancomycin are of great concern, especially since higher mortality rates in MRSA BSI have been associated with increased vancomycin MIC (≥ 2 mg/L in some studies) [5,6]. While several anti-MRSA agents such as ceftaroline, daptomycin and linezolid have been used as alternatives to glycopeptides (vancomycin and teicoplanin), limited clinical and pharmacodynamic (PD) comparative data are available to assess their utility in MRSA BSI [7][8][9].…”

Treatment strategies for persistent methicillin‐resistantStaphylococcus aureusbacteraemia

“…Notable from this publication was the every 8‐hour dosing strategy employed resulting in effective bacterial eradication from the bloodstream. In vitro data corroborate an every 8‐hour dosing strategy which optimizes the pharmacokinetic/pharmacodynamics of ceftaroline; however, additional clinical experience with standard and high‐dose has also been associated with clinical success …”

“…One of the first reports documenting successful clearance of persistent MRSA bacteraemia was a case series from Ho et al57 Notable from this publication was the every 8-hour dosing strategy employed resulting in effective bacterial eradication from the bloodstream. In vitro data corroborate an every 8-hour dosing strategy which optimizes the pharmacokinetic/pharmacodynamics of ceftaroline; however, additional clinical experience with standard and high-dose has also been associated with clinical success 56,[58][59][60][61][62][63]. A case series reported success with ceftaroline plus TMP-SMX for salvage therapy in 26/29 patients.…”

Nuevas cefalosporinas

“…Antimicrobianos tratados con daptomicina. La tasa global de mortalidad a los 30 días fue de 13% (n = 4) en pacientes con ceftarolina frente a 24% (n = 11) en pacientes con daptomicina y 11% (n = 6) en pacientes con vancomicina (p = 0,188) 28 , lo que sugiere que el uso de ceftarolina pudiera ser comparable al de vancomicina. Según esto, ceftarolina parece eficaz para bacteriemia por SARM como monoterapia y terapia combinada.…”

“…Usos potenciales de las nuevas cefalosporinasCeftarolina Ceftazidima/avibactam Ceftolozano/tazobactamBacteriemia por SARM26,27 Neumonía adquirida en el hospital y neumonía asociada al ventilador28 …”